Developer docs
API playgroundTry for free, no card

Search company profiles

On Target Laboratories

Full company profile

uuid0000y1m

Namestring
On Target Laboratories
Legal namestring
On Target Laboratories, Inc.
Company typeenum
Private
Founded yearint
2010
Descriptiontext

On Target Laboratories is a privately held biotechnology company developing small-molecule intraoperative molecular imaging agents that illuminate cancerous tissue in real time during surgery. The company's flagship product, CYTALUX (pafolacianine) injection, is the first and only FDA-approved targeted molecular imaging agent for intraoperative visualization of ovarian and lung cancer, combining a near-infrared fluorescent dye with a targeting ligand that binds folate receptors overexpressed on cancer cells. The technology traces to Philip S. Low's pioneering folate-receptor research at Purdue University and is administered as a single IV infusion prior to surgery to allow surgeons to detect additional malignant lesions — including sub-surface lesions invisible under white light — that would otherwise be left behind.

The company generates revenue through hospital purchases of CYTALUX for use in ovarian and lung cancer surgeries, with pricing not publicly disclosed but supported by a CMS New Technology Add-On Payment and dedicated ICD-10-PCS codes. On Target operates a direct enterprise field sales model: dedicated regional sales representatives partner with hospital operating rooms, pre-op, and pharmacy departments to drive clinical adoption protocols. As of mid-2025, more than 2,000 patients had been treated across U.S. states covering 85% of the population, with approximately 1,000 procedures in 2025 representing 125% growth over 2024.

On Target Laboratories is incorporated in Indiana with headquarters in West Lafayette, employs 11–50 people, and is backed by a syndicate including Johnson & Johnson Innovation, H.I.G. BioHealth Partners, Olympus, Helsinn, Elevate Ventures, 3B Future, and the Pension Fund of the Christian Church. The development pipeline targets expansion into prostate and colorectal cancers — indications that together with ovarian and lung address roughly 72% of all inpatient oncology procedures and an estimated 3 million procedures annually.

Short descriptiontext

On Target Laboratories is a privately held biotech company that develops and commercializes CYTALUX, the first FDA-approved targeted intraoperative molecular imaging agent used during ovarian and lung cancer surgery to illuminate malignant tissue in real time for hospital surgical teams.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWest Lafayette, United States
HQ citystring
West Lafayette
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
intraoperative molecular imaging, fluorescence-guided surgery, cancer imaging agents, folate receptor targeting, near-infrared imaging
Industry3 codes
PRIMARYHLAHADAH
Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAKAFAF
Gynecologic Oncology
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Pharmaceutical Preparations2834
Product category
Intraoperative Cancer Imaging Agents
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1CYTALUX Product Sales
TypeOne Time License
Description

Sale of CYTALUX (pafolacianine) injection, an FDA-approved optical imaging agent administered via IV infusion prior to surgery. Revenue generated from hospital purchases for use in ovarian and lung cancer surgery.

ontargetlabs.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1CYTALUX (pafolacianine) injection - pricing not publicly disclosed
ModelOtherBilling cadencePay-as-you-go
Notes

Product is prescribed for specific surgical procedures. Hospital reimbursement negotiated separately. CMS has issued NTAP (New Technology Add-On Payment) for CYTALUX in ovarian and lung cancer indications.

ontargetlabs.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1CYTALUX
Description

FDA-approved intraoperative molecular imaging agent (pafolacianine) injection for illuminating cancer during surgery, approved for ovarian cancer (November 2021) and lung cancer (December 2022)

ontargetlabs.com
Core offering1 text field

On Target Laboratories develops and commercializes CYTALUX (pafolacianine) injection, the first FDA-approved targeted molecular imaging agent that uses near-infrared fluorescence to illuminate ovarian and lung cancer tissue in real time during surgery. The product binds to folate receptors overexpressed on cancer cells, enabling surgeons to detect additional malignant lesions that may otherwise go unnoticed under standard white-light visualization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • In lung cancer trials, CYTALUX revealed hidden lesions in 20% of patients and identified previously unknown cancer in nearly 10% of cases
+5 more records
Product overview1 text field

On Target Laboratories is a biotech company that discovers and develops intraoperative molecular imaging agents. Their flagship product is CYTALUX (pafolacianine) injection, the first and only FDA-approved targeted molecular imaging agent capable of illuminating lung and ovarian cancer in real-time during surgery. The company is built on small molecule technology pioneered by Purdue University's Philip S. Low, PhD, utilizing near-infrared fluorescence to differentiate malignant from healthy tissue. Their development pipeline targets additional cancer types including prostate and colorectal cancers.

Product and service1 record
1CYTALUX (pafolacianine) injection
CategoryDiagnostic Imaging Pharmaceutical
Description

CYTALUX is an FDA-approved targeted near-infrared fluorescent imaging agent indicated for adult patients with ovarian cancer and lung cancer undergoing surgery. It binds to folate receptors overexpressed on cancer cells and is administered intravenously prior to surgery so surgeons can detect additional malignant tissue in real time using a near-infrared imaging system.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-03-07
Description

Collaboration to further explore targeted detection and real-time diagnosis of lung cancer with a molecular imaging agent. Mauna Kea Technologies provides Cellvizio confocal laser endomicroscopy system for use in conjunction with CYTALUX in clinical research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

On Target's molecular imaging technology is based on the pioneering work of Philip S. Low, PhD, Purdue University's Presidential Scholar for Drug Discovery. The company has deep ties to Purdue for research and intellectual property development.

Strategic tierSupportingTypeTechnology or Integration
Description

Olympus is listed as an investor supporting On Target's work. Olympus provides medical imaging technology that may complement CYTALUX visualization.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Radiopharmaceutical imaging and oncology company; comparable as a developer of targeted imaging agents for cancer, providing a strategic benchmark for On Target's path to scaled oncology imaging-agent commercialization.

TypeBroad incumbent
Description

Medical device incumbent with the SPY fluorescence imaging platform used intraoperatively; comparable because its NIR imaging systems are the typical hardware companion to CYTALUX in surgical oncology, and Stryker could conceivably develop or partner on competing imaging agents.

TypeBroad incumbent
Description

Robotic surgery leader with the Firefly NIR imaging system integrated into the da Vinci platform; directly comparable intraoperative fluorescence imaging technology used during oncology procedures where CYTALUX is administered.

TypeBroad incumbent
Description

Endoscopic imaging and surgical systems provider, including NIR-capable equipment; comparable as an existing On Target investor that also sells the OR imaging hardware needed to visualize CYTALUX and could expand into imaging agents.

5Carl Zeiss Meditec
TypeBroad incumbent
Description

Surgical microscopy and intraoperative fluorescence imaging provider (e.g., INFRARED 800, Blue 400); comparable because its OR imaging platforms are potential alternative visualization systems for CYTALUX and the company is active in surgical oncology visualization.

TypeDirect peer
Description

Cellvizio confocal laser endomicroscopy developer and an existing On Target collaboration partner; comparable as a real-time intraoperative cellular imaging company pursuing complementary lung cancer detection use cases alongside CYTALUX.

TypeEmerging player
Description

Radiopharmaceutical company with targeted diagnostic and therapeutic agents for oncology, including PSMA-targeted imaging; comparable as a competitor-developer of intra-procedural cancer visualization agents and a benchmark for theranostic commercial models.

TypeBroad incumbent
Description

Global diagnostic imaging company with contrast agents and imaging platforms; comparable as an established developer and distributor of imaging agents that complement surgical and radiology workflows relevant to CYTALUX.

TypeBroad incumbent
Description

Healthcare technology incumbent with image-guided therapy and surgical visualization offerings; comparable as a broad incumbent that could integrate or compete with intraoperative molecular imaging agents in hospital ORs.

TypeBroad incumbent
Description

Diversified medical device leader with surgical and intraoperative imaging solutions; comparable as a large incumbent that could enter the targeted intraoperative imaging agent space and leverage established hospital channels.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

On Target Laboratories

Intraoperative Cancer Imaging Agentsontargetlabs.com

On Target Laboratories is a privately held biotech company that develops and commercializes CYTALUX, the first FDA-approved targeted intraoperative molecular imaging agent used during ovarian and lung cancer surgery to illuminate malignant tissue in real time for hospital surgical teams.

What On Target Laboratories does

On Target Laboratories is a privately held biotechnology company developing small-molecule intraoperative molecular imaging agents that illuminate cancerous tissue in real time during surgery. The company's flagship product, CYTALUX (pafolacianine) injection, is the first and only FDA-approved targeted molecular imaging agent for intraoperative visualization of ovarian and lung cancer, combining a near-infrared fluorescent dye with a targeting ligand that binds folate receptors overexpressed on cancer cells. The technology traces to Philip S. Low's pioneering folate-receptor research at Purdue University and is administered as a single IV infusion prior to surgery to allow surgeons to detect additional malignant lesions — including sub-surface lesions invisible under white light — that would otherwise be left behind.

The company generates revenue through hospital purchases of CYTALUX for use in ovarian and lung cancer surgeries, with pricing not publicly disclosed but supported by a CMS New Technology Add-On Payment and dedicated ICD-10-PCS codes. On Target operates a direct enterprise field sales model: dedicated regional sales representatives partner with hospital operating rooms, pre-op, and pharmacy departments to drive clinical adoption protocols. As of mid-2025, more than 2,000 patients had been treated across U.S. states covering 85% of the population, with approximately 1,000 procedures in 2025 representing 125% growth over 2024.

On Target Laboratories is incorporated in Indiana with headquarters in West Lafayette, employs 11–50 people, and is backed by a syndicate including Johnson & Johnson Innovation, H.I.G. BioHealth Partners, Olympus, Helsinn, Elevate Ventures, 3B Future, and the Pension Fund of the Christian Church. The development pipeline targets expansion into prostate and colorectal cancers — indications that together with ovarian and lung address roughly 72% of all inpatient oncology procedures and an estimated 3 million procedures annually.

On Target Laboratories firmographics

Firmographics
Name
On Target Laboratories
Legal name
On Target Laboratories, Inc.
Website
https://ontargetlabs.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
51–100 employees
Short description
On Target Laboratories is a privately held biotech company that develops and commercializes CYTALUX, the first FDA-approved targeted intraoperative molecular imaging agent used during ovarian and lung cancer surgery to illuminate malignant tissue in real time for hospital surgical teams.
Ownership category
akta.pro rank

On Target Laboratories industry classification

Industry
Product category
Intraoperative Cancer Imaging Agents
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAHADAH
Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAKAFAF
Gynecologic Oncology
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)

Keywords

  • Intraoperative molecular imaging
  • Fluorescence-guided surgery
  • Cancer imaging agents
  • Folate receptor targeting
  • Near-infrared imaging

Where On Target Laboratories is headquartered

Location

Headquarters

HQ city
West Lafayette
HQ country
United States
HQ region
North America

Offices1 record

Markets served

On Target Laboratories business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. CYTALUX Product Sales: Sale of CYTALUX (pafolacianine) injection, an FDA-approved optical imaging agent administered via IV infusion prior to surgery. Revenue generated from hospital purchases for use in ovarian and lung cancer surgery.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goCYTALUX (pafolacianine) injection - pricing not publicly disclosed

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

On Target Laboratories product offering

Product offering

Core offering

On Target Laboratories develops and commercializes CYTALUX (pafolacianine) injection, the first FDA-approved targeted molecular imaging agent that uses near-infrared fluorescence to illuminate ovarian and lung cancer tissue in real time during surgery. The product binds to folate receptors overexpressed on cancer cells, enabling surgeons to detect additional malignant lesions that may otherwise go unnoticed under standard white-light visualization.

Product overview

On Target Laboratories is a biotech company that discovers and develops intraoperative molecular imaging agents. Their flagship product is CYTALUX (pafolacianine) injection, the first and only FDA-approved targeted molecular imaging agent capable of illuminating lung and ovarian cancer in real-time during surgery. The company is built on small molecule technology pioneered by Purdue University's Philip S. Low, PhD, utilizing near-infrared fluorescence to differentiate malignant from healthy tissue. Their development pipeline targets additional cancer types including prostate and colorectal cancers.

Differentiator

Problem solved

Functional benefit

Brands

  • CYTALUX: FDA-approved intraoperative molecular imaging agent (pafolacianine) injection for illuminating cancer during surgery, approved for ovarian cancer (November 2021) and lung cancer (December 2022)

Products and services

  • CYTALUX (pafolacianine) injection CYTALUX is an FDA-approved targeted near-infrared fluorescent imaging agent indicated for adult patients with ovarian cancer and lung cancer undergoing surgery. It binds to folate receptors overexpressed on cancer cells and is administered intravenously prior to surgery so surgeons can detect additional malignant tissue in real time using a near-infrared imaging system.

Quantifiable outcome

  • In lung cancer trials, CYTALUX revealed hidden lesions in 20% of patients and identified previously unknown cancer in nearly 10% of cases
  • +5 more outcomes

Companies that use On Target Laboratories

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles1 record

On Target Laboratories technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

On Target Laboratories partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and supporting.

  • Mauna Kea TechnologiescoreTechnology or Integration · 7 March 2023Collaboration to further explore targeted detection and real-time diagnosis of lung cancer with a molecular imaging agent. Mauna Kea Technologies provides Cellvizio confocal laser endomicroscopy system for use in conjunction with CYTALUX in clinical research.
  • Purdue UniversitycoreStrategic or Co-development PartnerOn Target's molecular imaging technology is based on the pioneering work of Philip S. Low, PhD, Purdue University's Presidential Scholar for Drug Discovery. The company has deep ties to Purdue for research and intellectual property development.
  • OlympussupportingTechnology or IntegrationOlympus is listed as an investor supporting On Target's work. Olympus provides medical imaging technology that may complement CYTALUX visualization.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

On Target Laboratories competitors and assessment

Company assessment

Emerging players

  • Lantheus Holdings: Radiopharmaceutical imaging and oncology company; comparable as a developer of targeted imaging agents for cancer, providing a strategic benchmark for On Target's path to scaled oncology imaging-agent commercialization.
  • Telix Pharmaceuticals: Radiopharmaceutical company with targeted diagnostic and therapeutic agents for oncology, including PSMA-targeted imaging; comparable as a competitor-developer of intra-procedural cancer visualization agents and a benchmark for theranostic commercial models.

Broad incumbents

  • Stryker: Medical device incumbent with the SPY fluorescence imaging platform used intraoperatively; comparable because its NIR imaging systems are the typical hardware companion to CYTALUX in surgical oncology, and Stryker could conceivably develop or partner on competing imaging agents.
  • Intuitive Surgical: Robotic surgery leader with the Firefly NIR imaging system integrated into the da Vinci platform; directly comparable intraoperative fluorescence imaging technology used during oncology procedures where CYTALUX is administered.
  • Olympus: Endoscopic imaging and surgical systems provider, including NIR-capable equipment; comparable as an existing On Target investor that also sells the OR imaging hardware needed to visualize CYTALUX and could expand into imaging agents.
  • Carl Zeiss Meditec: Surgical microscopy and intraoperative fluorescence imaging provider (e.g., INFRARED 800, Blue 400); comparable because its OR imaging platforms are potential alternative visualization systems for CYTALUX and the company is active in surgical oncology visualization.
  • Bracco Imaging: Global diagnostic imaging company with contrast agents and imaging platforms; comparable as an established developer and distributor of imaging agents that complement surgical and radiology workflows relevant to CYTALUX.
  • Philips (Image-Guided Therapy): Healthcare technology incumbent with image-guided therapy and surgical visualization offerings; comparable as a broad incumbent that could integrate or compete with intraoperative molecular imaging agents in hospital ORs.
  • Medtronic: Diversified medical device leader with surgical and intraoperative imaging solutions; comparable as a large incumbent that could enter the targeted intraoperative imaging agent space and leverage established hospital channels.

Direct peers

  • Mauna Kea Technologies: Cellvizio confocal laser endomicroscopy developer and an existing On Target collaboration partner; comparable as a real-time intraoperative cellular imaging company pursuing complementary lung cancer detection use cases alongside CYTALUX.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

On Target Laboratories social profiles

Digital presence

On Target Laboratories financial estimates

Financial estimate

Revenue estimate

Valuation estimate

On Target Laboratories leadership team

Management profile

Number of profiles

Profiles13 records

On Target Laboratories funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

On Target Laboratories M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about On Target Laboratories

What does On Target Laboratories do?

On Target Laboratories develops and commercializes CYTALUX (pafolacianine) injection, the first FDA-approved targeted molecular imaging agent that uses near-infrared fluorescence to illuminate ovarian and lung cancer tissue in real time during surgery. The product binds to folate receptors overexpressed on cancer cells, enabling surgeons to detect additional malignant lesions that may otherwise go unnoticed under standard white-light visualization.

Is On Target Laboratories a public or private company?

On Target Laboratories is a private company. It is classified as venture growth investor backed and is currently operating.

When was On Target Laboratories founded?

On Target Laboratories was founded in 2010. It employs 51 to 100 people.

Where is On Target Laboratories based?

On Target Laboratories is headquartered in West Lafayette, United States, in the North America region.

How does On Target Laboratories make money?

One revenue line is on record: CYTALUX Product Sales.

Who are On Target Laboratories's main competitors?

Emerging players on record are Lantheus Holdings and Telix Pharmaceuticals. Broad incumbents are Stryker, Intuitive Surgical, Olympus, Carl Zeiss Meditec, Bracco Imaging, Philips (Image-Guided Therapy) and Medtronic. Mauna Kea Technologies is listed as a direct peer.

Does On Target Laboratories have an API?

No public API is recorded for On Target Laboratories.

What industry is On Target Laboratories in?

On Target Laboratories's product category is Intraoperative Cancer Imaging Agents. Its primary akta.pro industry code is HLAHADAH, Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence), with a secondary code of HLAKAFAF, Gynecologic Oncology. Its NAICS code is 3254 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Building IndianaOn Target Laboratories Secures $30M for New Cancer Imaging AgentOn Target Laboratories announced the completion of a $30 million Series C financing round to accelerate the commercialization of its cancer imaging agent, CYTALUX. The investment was backed by strategic partners including Olympus Innovation Ventures and Johnson & Johnson Innovation – JJDC, Inc., alongside other private equity firms. This funding follows recent regulatory approvals for reimbursement from CMS and aligns with the rollout of compatible surgical camera technology by Stryker.PR NewswireOn Target Laboratories Appoints Bill Peters as CEOOn Target Laboratories appointed Bill Peters as president and CEO, succeeding Ben Lundgren. Peters brings over 20 years of medical technology leadership, including a decade at ConMed. He will join the board and aim to scale the company.VC News DailyOn Target Laboratories Announces $30M Series COn Target Laboratories, a privately held biotechnology company based in West Lafayette, Indiana, has completed a $30 million Series C financing round. The funding will accelerate commercialization of CYTALUX, the company's FDA-approved molecular imaging agent that illuminates lung and ovarian cancer during surgery, enabling surgeons to detect more cancer for resection. The round was backed by investors including H.I.G. Capital, Johnson & Johnson Innovation - JJDC, Inc., and Olympus Innovation Ventures.PR NewswireOn Target Laboratories Announces Publication in Journal of Thoracic and Cardiovascular Surgery Phase 3 ELUCIDATE Trial of CYTALUX® (pafolacianine) Injection for Intraoperative Imaging of Lung CancerOn Target Laboratories announced publication of Phase 3 ELUCIDATE trial results for CYTALUX (pafolacianine) injection in the Journal of Thoracic and Cardiovascular Surgery, with clinically significant events occurring in 53% of lung cancer patients (n=53/100, p<0.0001). The FDA expanded CYTALUX's indication to lung cancer in December 2022 following prior ovarian cancer approval in 2021, making it the first and only targeted molecular imaging agent for intraoperative visualization of both cancer types. Surgeons changed their surgical plan in 29% of patients, with 73% of additional cancerous lesions discovered lying outside the planned resection field, and no drug-related serious adverse events were reported.PR NewswireOn Target Laboratories Announces Expanded Indication of CYTALUX® (pafolacianine) injection for Detection of Lung Cancer During SurgeryOn Target Laboratories announced that the FDA has approved an expanded indication for CYTALUX (pafolacianine) injection, making it the first and only targeted molecular imaging agent approved to illuminate lung cancer intraoperatively during surgery, building on its prior 2021 approval for ovarian cancer. The approval was based on the ELUCIDATE Phase 3 trial demonstrating CYTALUX's ability to localize lung lesions that may have otherwise been missed, with up to 55% of lung cancer patients who undergo surgery experiencing recurrence. The company stated this represents an important step forward for the more than 220,000 people in the U.S. diagnosed with lung cancer each year.Clinical Trials ArenaCytalux (pafolacianine) for Identification of Ovarian CancerOn Target Laboratories developed Cytalux, a targeted fluorescent marker designed to help surgeons identify and remove ovarian cancer lesions during surgery. The drug received FDA approval in November 2021 after being granted priority review and fast-track designation for this indication. Clinical trials demonstrated that the agent could detect malignant lesions undetected by normal visual or tactile assessment in nearly 27% of patients.PR NewswireOn Target Laboratories Completes ELUCIDATE Phase 3 Clinical Trial Investigating the Use of CYTALUX™ (pafolacianine) injection in Cancer in the LungOn Target Laboratories announced the completion of the Phase 3 ELUCIDATE trial investigating CYTALUX (pafolacianine) injection as an intraoperative imaging agent for identifying lung cancer during thoracic surgery. The trial successfully achieved its primary endpoint and was completed ahead of schedule during the pandemic, with full results to be shared at a future date. CYTALUX is already FDA-approved for ovarian cancer and targets folate receptors commonly found on many cancers.PR NewswireOn Target Laboratories Announces FDA Approval of CYTALUX™ (pafolacianine) injection for Identification of Ovarian Cancer During SurgeryOn Target Laboratories received FDA approval for CYTALUX, the first targeted fluorescent imaging agent for intraoperative identification of ovarian cancer, administered via IV one hour before surgery to illuminate malignant lesions under near-infrared light. In the Phase 3 clinical trial, CYTALUX detected additional cancer in 27% of patients, and among patients who underwent interval debulking surgery after chemotherapy, the detection rate reached 40%. The company plans to pursue broader adoption as a standard of care and is currently investigating the technology for lung cancer in a Phase 3 trial.PR NewswireFDA Approves New Imaging Drug to Help Identify Ovarian Cancer LesionsThe FDA approved Cytalux (pafolacianine), an imaging drug developed by On Target Laboratories designed to help surgeons identify ovarian cancer lesions during surgery by binding to overproduced proteins and illuminating under fluorescent light. In clinical trials of 134 women, 26.9% had at least one cancerous lesion detected that was not observed through standard visual or tactile inspection. Ovarian cancer is the deadliest of all female reproductive cancers, with the American Cancer Society estimating over 13,000 deaths in 2021.